JP2022507295A5 - - Google Patents
Info
- Publication number
- JP2022507295A5 JP2022507295A5 JP2021525789A JP2021525789A JP2022507295A5 JP 2022507295 A5 JP2022507295 A5 JP 2022507295A5 JP 2021525789 A JP2021525789 A JP 2021525789A JP 2021525789 A JP2021525789 A JP 2021525789A JP 2022507295 A5 JP2022507295 A5 JP 2022507295A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- variable domain
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862767509P | 2018-11-14 | 2018-11-14 | |
| US62/767,509 | 2018-11-14 | ||
| US201962820718P | 2019-03-19 | 2019-03-19 | |
| US62/820,718 | 2019-03-19 | ||
| US201962886872P | 2019-08-14 | 2019-08-14 | |
| US62/886,872 | 2019-08-14 | ||
| US201962931746P | 2019-11-06 | 2019-11-06 | |
| US62/931,746 | 2019-11-06 | ||
| PCT/US2019/061278 WO2020102422A1 (en) | 2018-11-14 | 2019-11-13 | THERAPEUTIC SIRPα ANTIBODIES |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022507295A JP2022507295A (ja) | 2022-01-18 |
| JP2022507295A5 true JP2022507295A5 (https=) | 2022-11-21 |
Family
ID=70730617
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021525789A Withdrawn JP2022507295A (ja) | 2018-11-14 | 2019-11-13 | 治療用ＳＩＲＰα抗体 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US11202828B2 (https=) |
| EP (1) | EP3880239A4 (https=) |
| JP (1) | JP2022507295A (https=) |
| CN (1) | CN113573728A (https=) |
| AU (1) | AU2019380503A1 (https=) |
| BR (1) | BR112021009325A2 (https=) |
| CA (1) | CA3119748A1 (https=) |
| WO (1) | WO2020102422A1 (https=) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL262251B2 (en) | 2016-04-14 | 2023-09-01 | Ose Immunotherapeutics | New anti-syrap antibodies and their medical applications |
| JOP20190009A1 (ar) | 2016-09-21 | 2019-01-27 | Alx Oncology Inc | أجسام مضادة ضد بروتين ألفا منظم للإشارات وطرق استخدامها |
| PE20201265A1 (es) | 2018-03-21 | 2020-11-19 | Alx Oncology Inc | Anticuerpos contra proteina alfa reguladora de senal y metodos de uso |
| CN112574310B (zh) * | 2020-12-11 | 2023-05-05 | 浙江博锐生物制药有限公司 | 抗SIRPα抗体及其用途 |
| WO2022127901A1 (en) * | 2020-12-18 | 2022-06-23 | Lanova Medicines Development Co., Ltd. | BISPECIFIC ANTIBODIES TARGETING SIRPα AND PD-L1 |
| CN117355539A (zh) * | 2021-05-28 | 2024-01-05 | 百奥泰生物制药股份有限公司 | 抗SIRPα抗体及其应用 |
| TW202317620A (zh) | 2021-06-04 | 2023-05-01 | 德商百靈佳殷格翰國際股份有限公司 | 抗ＳＩＲＰα抗體 |
| CN113956363B (zh) * | 2021-10-13 | 2023-03-31 | 宜明昂科生物医药技术（上海）股份有限公司 | 靶向cd47和cd24的重组融合蛋白及其制备和用途 |
| CN117447592B (zh) * | 2022-07-26 | 2024-05-28 | 北京东方百泰生物科技股份有限公司 | 一种抗Siglec-15单克隆抗体、其抗原结合片段及其应用 |
| CN115819586B (zh) * | 2022-10-13 | 2023-10-31 | 珠海市丽珠单抗生物技术有限公司 | 抗人SIRPα单克隆抗体及其用途 |
| EP4619435A1 (en) | 2022-11-16 | 2025-09-24 | Boehringer Ingelheim International GmbH | Predictive efficacy biomarkers for anti-sirpa antibodies |
| WO2024200820A1 (en) | 2023-03-30 | 2024-10-03 | Ose Immunotherapeutics | Method of synthesis of targeted lipid nanoparticle and uses thereof |
| EP4687991A1 (en) | 2023-03-30 | 2026-02-11 | Ose Immunotherapeutics | Lipid-based nanoparticle targeted at activated immune cells for the expression of immune cell enhancing molecule and use thereof |
| WO2024220895A1 (en) * | 2023-04-20 | 2024-10-24 | Twist Bioscience Corporation | Antibodies and variant nucleic acid libraries for sirp-alpha |
| CN116514980B (zh) * | 2023-04-23 | 2025-12-16 | 杭州美赛生物医药科技有限公司 | 抗SIRPα抗体及其应用 |
| CN118047874B (zh) * | 2024-02-19 | 2025-02-18 | 中科德佑(山西)生物科技有限公司 | 一种双特异性抗体及其与t细胞在制备治疗肿瘤药物中的应用 |
| CN118791601B (zh) * | 2024-07-24 | 2025-11-14 | 苏州大学 | 一株可改善结核分枝杆菌耐药性的抗Rv0340单克隆抗体及其应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU4128089A (en) * | 1988-09-15 | 1990-03-22 | Rorer International (Overseas) Inc. | Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same |
| NZ611428A (en) * | 2010-12-08 | 2015-07-31 | Stemcentrx Inc | Novel modulators and methods of use |
| KR102010098B1 (ko) * | 2011-08-17 | 2019-08-13 | 더 리전트 오브 더 유니버시티 오브 캘리포니아 | 인테그린 알파-v 베타-8에 결합하는 항체 |
| PT2780371T (pt) * | 2011-11-16 | 2019-01-30 | Adrenomed Ag | Anticorpo anti-adrenomedulina (adm) ou fragmento de anticorpo anti-adm ou uma estrutura não ig anti-adm para a regulação do equilíbrio de fluidos num doente com uma doença aguda ou crónica |
| WO2013109974A2 (en) | 2012-01-20 | 2013-07-25 | Genzyme Corporation | Anti-cxcr3 antibodies |
| RU2748401C2 (ru) * | 2015-09-18 | 2021-05-25 | Арч Онколоджи, Инк. | Терапевтические антитела к CD47 |
| BR112018070823A2 (pt) * | 2016-04-14 | 2019-02-05 | Ose Immunotherapeutics | anticorpo sirpa anti-humano ou fragmento de ligação a antígeno do mesmo ou mimético de anticorpo de ligação a antígeno, composição farmacêutica, produto de combinação, molécula de ácido nucleico isolada, vetor, célula hospedeira isolada, polipeptídeo, métodos para fabricar um anticorpo, in vitro ou ex vivo para determinar células positivas para sirpa, de diagnóstico e para prever a resposta de um sujeito, e, uso de um anticorpo anti-sirpa ou um fragmento de ligação a antígeno do mesmo ou um mimético de ligação a anticorpo e in vitro ou ex vivo de pelo menos um anticorpo sirpa anti-humano ou fragmento de ligação a antígeno do mesmo ou mimético de anticorpo de ligação a antígeno. |
| JOP20190009A1 (ar) * | 2016-09-21 | 2019-01-27 | Alx Oncology Inc | أجسام مضادة ضد بروتين ألفا منظم للإشارات وطرق استخدامها |
| KR102642385B1 (ko) | 2017-02-06 | 2024-03-04 | 오리오니스 바이오사이언시스 엔브이 | 표적화된 키메라 단백질 및 이의 용도 |
| KR102702926B1 (ko) * | 2017-04-13 | 2024-09-06 | 사이로파 비.브이. | 항-sirp 알파 항체 |
-
2019
- 2019-11-13 JP JP2021525789A patent/JP2022507295A/ja not_active Withdrawn
- 2019-11-13 EP EP19885043.0A patent/EP3880239A4/en not_active Withdrawn
- 2019-11-13 US US16/682,893 patent/US11202828B2/en active Active
- 2019-11-13 WO PCT/US2019/061278 patent/WO2020102422A1/en not_active Ceased
- 2019-11-13 BR BR112021009325-7A patent/BR112021009325A2/pt not_active Application Discontinuation
- 2019-11-13 CA CA3119748A patent/CA3119748A1/en not_active Withdrawn
- 2019-11-13 AU AU2019380503A patent/AU2019380503A1/en not_active Withdrawn
- 2019-11-13 CN CN201980087951.8A patent/CN113573728A/zh not_active Withdrawn
-
2021
- 2021-11-24 US US17/534,774 patent/US20220226469A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022507295A5 (https=) | ||
| US11858991B2 (en) | LAG-3-binding molecules and methods of use thereof | |
| US11202828B2 (en) | Therapeutic SIRP-α antibodies | |
| JP6955507B2 (ja) | Ｐｄ‐１及びｃｔｌａ‐４との免疫応答性を有する二重特異性並びにその使用方法 | |
| US20220025050A1 (en) | Bifunctional molecule directed against human pd-1 | |
| US11167029B2 (en) | Combination of a CD30XCD16 antibody with a PD-1 antagonist for therapy | |
| JP2019500892A5 (https=) | ||
| KR20180093127A (ko) | Pd-1-결합 분자 및 그것의 사용 방법 | |
| JP2019500891A5 (https=) | ||
| RU2018126297A (ru) | Антитела, нацеленные на cd32b, и способы их применения | |
| JP7480307B2 (ja) | 免疫細胞関与効果を調節するための手段および方法 | |
| US20230279108A1 (en) | Therapeutic sirp-alpha antibodies | |
| JP2023543896A5 (https=) | ||
| WO2023147331A1 (en) | Bispecific molecule with tunable affinity to a targetted antigen | |
| JP2023517889A5 (https=) | ||
| JP7378567B2 (ja) | Ｌａｇ‐３結合分子及びその使用方法 | |
| BR112017026330B1 (pt) | Molécula de ligação de lag-3 que compreende um domínio de ligação a lag-3 capaz de se ligar tanto ao lag-3 humano quanto ao lag-3 de macaco cynomolgus |